BioCentury | Jan 28, 2013
Company News

Morria Biopharmaceuticals management update

Morria Biopharmaceuticals plc , London, U.K. Business: Inflammation Hired: Alan Harris as CMO, currently adjunct professor of medicine at New York University Langone Medical School WIR Staff Inflammation Other...
BioCentury | Jul 9, 2012
Company News

Morria Biopharmaceuticals management update

Morria Biopharmaceuticals plc , London, U.K. Business: Inflammation Transitioned: Alan Harris to CMO from chief medical consultant WIR Staff Inflammation...
BioCentury | Sep 30, 2010
Distillery Therapeutics

Indication: Cancer

...collaboration with Pfizer Inc. to test the company's PLA2G4A inhibitor in animal models of cancer. Morria Biopharmaceuticals plc's...
BioCentury | Jul 15, 2010
Distillery Therapeutics

Indication: Dermatology

...of contact dermatitis and inflammatory bowel disease (IBD) and optimizing the analogs for systemic administration. Morria Biopharmaceuticals plc's...
BioCentury | Jul 12, 2010
Clinical News

MRX-4: Final Phase II data

...sneezing, frontal headache, nasal congestion and ear/palate itching) vs. placebo (see BioCentury, Nov. 10, 2008). Morria Biopharmaceuticals plc...
BioCentury | Apr 26, 2010
Clinical News

MRX-6: Phase II started

...to evaluate topical MRX-6 administered twice daily for 21 days in up to 80 patients. Morria Biopharmaceuticals plc...
BioCentury | Aug 31, 2009
Clinical News

MRX-6: Phase II start

...MRX-6 given twice daily vs. an undisclosed topical corticosteroid for 21 days in 80 patients. Morria Biopharmaceuticals plc...
BioCentury | Nov 13, 2008
Distillery Therapeutics

Indication: Neurology

...I, II and III trials to treat a range of metabolic, cardiovascular and neurological indications. Morria Biopharmaceuticals plc's...
BioCentury | Nov 13, 2008
Targets & Mechanisms

PLAyground in Alzheimer's

...sufficient amounts of arachidonic acid" needed for normal cell function, said Yuval Cohen, president of Morria Biopharmaceuticals plc...
...Gladstone Institute of Neurological Disease , San Francisco, Calif. Harvard Medical School , Boston, Mass. Morria Biopharmaceuticals plc...
BioCentury | Nov 10, 2008
Clinical News

MRX-4: Phase II data

...twice daily for 6 days followed by an intranasal dose of allergen on day 7. Morria Biopharmaceuticals plc...
Items per page:
1 - 10 of 19
BioCentury | Jan 28, 2013
Company News

Morria Biopharmaceuticals management update

Morria Biopharmaceuticals plc , London, U.K. Business: Inflammation Hired: Alan Harris as CMO, currently adjunct professor of medicine at New York University Langone Medical School WIR Staff Inflammation Other...
BioCentury | Jul 9, 2012
Company News

Morria Biopharmaceuticals management update

Morria Biopharmaceuticals plc , London, U.K. Business: Inflammation Transitioned: Alan Harris to CMO from chief medical consultant WIR Staff Inflammation...
BioCentury | Sep 30, 2010
Distillery Therapeutics

Indication: Cancer

...collaboration with Pfizer Inc. to test the company's PLA2G4A inhibitor in animal models of cancer. Morria Biopharmaceuticals plc's...
BioCentury | Jul 15, 2010
Distillery Therapeutics

Indication: Dermatology

...of contact dermatitis and inflammatory bowel disease (IBD) and optimizing the analogs for systemic administration. Morria Biopharmaceuticals plc's...
BioCentury | Jul 12, 2010
Clinical News

MRX-4: Final Phase II data

...sneezing, frontal headache, nasal congestion and ear/palate itching) vs. placebo (see BioCentury, Nov. 10, 2008). Morria Biopharmaceuticals plc...
BioCentury | Apr 26, 2010
Clinical News

MRX-6: Phase II started

...to evaluate topical MRX-6 administered twice daily for 21 days in up to 80 patients. Morria Biopharmaceuticals plc...
BioCentury | Aug 31, 2009
Clinical News

MRX-6: Phase II start

...MRX-6 given twice daily vs. an undisclosed topical corticosteroid for 21 days in 80 patients. Morria Biopharmaceuticals plc...
BioCentury | Nov 13, 2008
Distillery Therapeutics

Indication: Neurology

...I, II and III trials to treat a range of metabolic, cardiovascular and neurological indications. Morria Biopharmaceuticals plc's...
BioCentury | Nov 13, 2008
Targets & Mechanisms

PLAyground in Alzheimer's

...sufficient amounts of arachidonic acid" needed for normal cell function, said Yuval Cohen, president of Morria Biopharmaceuticals plc...
...Gladstone Institute of Neurological Disease , San Francisco, Calif. Harvard Medical School , Boston, Mass. Morria Biopharmaceuticals plc...
BioCentury | Nov 10, 2008
Clinical News

MRX-4: Phase II data

...twice daily for 6 days followed by an intranasal dose of allergen on day 7. Morria Biopharmaceuticals plc...
Items per page:
1 - 10 of 19